TERF2

Across TCGA pan-cancer cohorts, TERF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TERF2 data layer compared with 17 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TERF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TERF2 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, PDAC, and HNSC are the cancer types where TERF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.473	0.289	.009	16	view →
PDAC	DFS	Tertile	All	0.841	0.669	.011	14	view →
HNSC	DFS	Quartile	II,III,IV	0.615	0.847	.009	12	view →
LSCC	OS	Tertile	III,IV	0.591	1.000	.017	12	view →
CCRCC	DFS	Tertile	II,III,IV	0.784	0.260	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TERF2–GBM (OS)

Open the GBM breakdown →